^
    4years
    A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas. (PubMed, Br J Cancer)
    At the RP2D (40 mg Q8h), TSR-011 demonstrated a favourable safety profile with acceptable QTc changes. Limited clinical activity was observed. Based on the competitive ALK inhibitor landscape and benefit/risk considerations, further TSR-011 development was discontinued.
    Clinical • P1 data • Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    belizatinib (TSR-011)